Moreover, SURPASS-CVOT study will compare dulaglutide vs. tirzepatide on cardiovascular outcomes in people with T2D and established cardiovascular disease and will provide evidence on whether the dual GLP-1/GIP co-agonist is as safe as GLP-1 RAs. Here, GCG is linked to cardiovascular disorder.